Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

103.39 +0.08 (+0.07%)
Streaming Delayed Price Updated: 1:07 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Exact Sciences (EXAS) Q4 2024 Earnings Call Transcript ↗
EXAS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Exact Sciences Stock Slides On Q4 Earnings: The Details ↗
Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here's a look at the key details from the quarter. 
Via Benzinga
News headline image
Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s... 
Via StockStory
News headline image
Exact Sciences Announces Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
News headline image
Trump Calls For More Tariffs, Federal Reserve Minutes On Deck: What's Driving Markets Wednesday? ↗
All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors. 
Via Benzinga
Topics Economy Government World Trade
News headline image
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
From Exact Sciences Corp.
Via Business Wire
News headline image
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
From Exact Sciences Corp.
Via Business Wire
News headline image
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone ↗
The company is working to expand the uses and reimbursement for its blood-based tests for cancer. 
Via Investor's Business Daily
News headline image
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?' ↗
The company is facing numerous headline risks. But not all of them are legitimate, says one analyst. 
Via Investor's Business Daily
News headline image
(EXAS) - Analyzing Exact Sciences's Short Interest ↗
 
Via Benzinga
News headline image
What 19 Analyst Ratings Have To Say About Exact Sciences ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 19, 2025 ↗
 
Via Benzinga
News headline image
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
News headline image
Forecasting The Future: 19 Analyst Projections For Exact Sciences ↗
 
Via Benzinga
News headline image
2 Healthcare Stocks to Buy Hand Over Fist in January ↗
Via The Motley Fool
News headline image
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market ↗
Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are set for 2025 launch. 
Via Benzinga
News headline image
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
From Exact Sciences Corp.
Via Business Wire
News headline image
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP. 
Via Benzinga
News headline image
Why Is Exact Sciences Stock Trading Higher On Monday? ↗
Centers for Medicare & Medicaid Services finalizes 2025 pricing for Exact Sciences' Cologuard Plus, raising Medicare reimbursement by 16% and boosting growth projections for next year. 
Via Benzinga
News headline image
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks ↗
U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.'s largest trading partners - Canada and Mexico - with... 
Via Benzinga
Topics Government
News headline image
Exact Sciences to Participate in December Investor Conferences
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? ↗
The company reported lighter-than-expected third-quarter sales due to issues with physician order rates. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point ↗
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.